NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, announces filing of a class action lawsuit on behalf of purchasers of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) from June 17, 2015 through August 10, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Dr. Reddy’s investors under the federal securities laws.
To join the Dr. Reddy’s class action, go to http://www.rosenlegal.com/cases-1191.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 24, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1191.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



